First-day Discharge Enhanced Recovery After Surgery Protocol for Minimal Invasive Colorectal Surgery
Launched by CORPORACION PARC TAULI · Aug 23, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special approach called the Enhanced Recovery After Surgery (ERAS) protocol for patients undergoing minimally invasive surgeries for colorectal disorders, specifically right colectomy or sigmoidectomy. The goal is to see if patients can safely go home just one day after surgery while still receiving support from healthcare professionals at home. The hope is that this method can help patients recover faster and reduce the chances of needing to return to the hospital after their surgery.
To participate in this trial, patients need to be between the ages of 65 and 74 and meet certain criteria, such as having a planned minimally invasive surgery for a non-emergency condition, and having family support to assist them at home. Patients who have had certain health issues or treatments, like recent chemotherapy or specific blood conditions, are not eligible. If you join the study, you can expect to follow a set recovery plan and have regular check-ins from healthcare providers after you leave the hospital, helping to ensure a smooth recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pacients who undergo a minimal invasive sigmoidectomy or right colectomy.
- • Benign or malignant desease.
- • No expected stoma
- • ASA ≤ III
- • Family support
- Exclusion Criteria:
- • Emergency surgery
- • Anticoagulant therapy
- • Recent immunosupresor therapy (less than one month)
- • Anemia (Male Hb \>120 g/L, Female Hb \>110 g/L)
- • Malnutrition (Albumine \>35 g/L)
- • Dementia
- • Moderate or high frailty
- • Syncronic neoplasia
- • Previous colorectal surgery
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Trial Officials
Anna Pallisera-Lloveras, MD, PhD
Principal Investigator
Corporacio Parc Tauli. Parc Tauli University Hospital
Laura Mora-Lopez, MD, PhD
Study Director
Corporacio Parc Tauli. Parc Tauli University Hospital
Oriol Pino-Perez, MD
Principal Investigator
Corporacio Parc Tauli. Parc Tauli University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported